|
ev3 Stage: Growth Date of Investment: 2000 Web Site : http://www.ev3.net Stock Symbol : NASDAQ: EVVV |
 |
ev3, headquartered in Plymouth, MN, is a leading global endovascular device company focused on the treatment of peripheral vascular and neurovascular disease. The company’s product portfolio includes a broad spectrum of over 100 products, including stents, embolic protection, PTA balloons and atherectomy devices for the peripheral vascular market, as well as embolic coils, liquid embolics, flow diversion, and access products for the neurovascular market.
Warburg Pincus founded ev3 in 2000, and has fostered the Company's product development strategy by funding internal development programs and strategic acquisitions. Warburg Pincus also helped recruit a roster of highly talented managers with extensive experience in all aspects of the interventional devices business. ev3 completed an initial public offering in June 2005 and a follow-on public offering in April 2007. In October 2007, ev3 acquired FoxHollow Technologies, a developer of atherectomy devices for the treatment of peripheral vascular disease. In June 2009, ev3 acquired Chestnut Medical Technologies, a privately held company focused on developing neurovascular devices, including the Pipeline Embolization Device for aneurysms.
